Leerink Partnrs Issues Pessimistic Outlook for PTCT Earnings

Key Points

• Leerink Partners has significantly lowered its Q1 2026 earnings per share estimate for PTC Therapeutics from ($1.32) to ($1.40), forecasting continued losses.
• Despite the pessimistic outlook, PTC Therapeutics has received several "Buy" ratings from analysts, with price targets ranging from $63.00 to $118.00.
• Insider trading activity includes substantial share sales by high-ranking company officials, with a total of 249,735 shares sold over the last ninety days.

PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Analysts at Leerink Partnrs dropped their Q1 2026 earnings per share (EPS) estimates for PTC Therapeutics in a research note issued to investors on Wednesday, October 15th. Leerink Partnrs analyst J. Schwartz now forecasts that the biopharmaceutical company will post earnings per share of ($1.40) for the quarter, down from their prior estimate of ($1.32). The consensus estimate for PTC Therapeutics' current full-year earnings is ($4.52) per share. Leerink Partnrs also issued estimates for PTC Therapeutics' Q2 2026 earnings at ($1.40) EPS, Q3 2026 earnings at ($0.74) EPS, Q4 2026 earnings at ($0.68) EPS, FY2026 earnings at ($3.47) EPS and FY2027 earnings at ($3.82) EPS.

PTCT has been the subject of a number of other reports. Royal Bank Of Canada restated an "outperform" rating and issued a $63.00 target price (up from $60.00) on shares of PTC Therapeutics in a research note on Friday, August 8th. UBS Group lifted their price objective on PTC Therapeutics from $71.00 to $80.00 and gave the stock a "buy" rating in a research report on Tuesday, July 29th. Robert W. Baird set a $70.00 price objective on PTC Therapeutics in a research report on Friday, August 8th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $118.00 price objective on shares of PTC Therapeutics in a research report on Wednesday, September 3rd. Finally, Bank of America lowered their price objective on PTC Therapeutics from $82.00 to $76.00 and set a "buy" rating for the company in a research report on Wednesday, August 20th. Nine research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, PTC Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $69.00.

PTC Therapeutics Stock Performance

Shares of NASDAQ:PTCT opened at $65.95 on Monday. PTC Therapeutics has a twelve month low of $35.95 and a twelve month high of $69.48. The firm has a market cap of $5.24 billion, a PE ratio of 9.46 and a beta of 0.55. The business has a fifty day moving average of $57.39 and a 200-day moving average of $51.11.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, beating analysts' consensus estimates of ($1.07) by $0.24. PTC Therapeutics had a negative return on equity of 106.31% and a net margin of 35.65%.The company had revenue of $178.88 million during the quarter, compared to analyst estimates of $173.01 million. During the same period last year, the company posted ($1.29) earnings per share. The firm's quarterly revenue was down 4.2% compared to the same quarter last year. PTC Therapeutics has set its FY 2025 guidance at EPS.

Insiders Place Their Bets

In related news, insider Neil Gregory Almstead sold 55,000 shares of the stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $66.05, for a total value of $3,632,750.00. Following the sale, the insider directly owned 100,625 shares in the company, valued at $6,646,281.25. This trade represents a 35.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Emma Reeve sold 25,562 shares of the stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $65.96, for a total transaction of $1,686,069.52. Following the completion of the sale, the director owned 10,332 shares in the company, valued at $681,498.72. This represents a 71.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 249,735 shares of company stock worth $15,467,670 over the last ninety days. Company insiders own 5.50% of the company's stock.

Hedge Funds Weigh In On PTC Therapeutics

Several institutional investors have recently modified their holdings of PTCT. Nuveen LLC bought a new position in shares of PTC Therapeutics during the 1st quarter valued at about $51,427,000. Wellington Management Group LLP lifted its holdings in shares of PTC Therapeutics by 13.2% during the 1st quarter. Wellington Management Group LLP now owns 5,419,172 shares of the biopharmaceutical company's stock valued at $276,161,000 after purchasing an additional 632,049 shares in the last quarter. Hood River Capital Management LLC lifted its holdings in shares of PTC Therapeutics by 654.4% during the 2nd quarter. Hood River Capital Management LLC now owns 636,502 shares of the biopharmaceutical company's stock valued at $31,087,000 after purchasing an additional 552,130 shares in the last quarter. State Street Corp lifted its holdings in shares of PTC Therapeutics by 22.1% during the 2nd quarter. State Street Corp now owns 2,996,454 shares of the biopharmaceutical company's stock valued at $146,347,000 after purchasing an additional 541,558 shares in the last quarter. Finally, Driehaus Capital Management LLC lifted its holdings in shares of PTC Therapeutics by 45.3% during the 1st quarter. Driehaus Capital Management LLC now owns 1,512,645 shares of the biopharmaceutical company's stock valued at $77,084,000 after purchasing an additional 471,586 shares in the last quarter.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.